Survey Regarding the use of Biosimilars compared to the use of Reference Biological Drugs

Dennis W. Raisch, RPh, PhD1,2; Maarten IJzerman, PhD2; Charles L. Bennett, MD, PhD3

1University of New Mexico, College of Pharmacy; 
2Department of Health Technology and Services Research, University of Twente;
3The Southern Network on Adverse Reactions (SONAR) Project, University of South Carolina, College of Pharmacy



This survey is designed to gather perceptions about reference biologicals compared to biosimilars, which can be marketed after a biological product reaches its patent expiration date. 

This survey consists of three parts: (1) questions about your preferences with regard to reference biologicals and biosimilars, (2) questions about different criteria in the decision-making process that are important to you, and (3) questions about your demographics. 


We are asking for your opinion. There are no right or wrong answers. All your responses are anonymous.


It takes about 10-15 minutes to complete the questionnaire. Thank you very much for your time and effort!

There are 24 questions in this survey.